- Home
- LZ vs ORKA Comparison
LZ vs ORKA Comparison
Compare LZ & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LZ
- ORKA
- Stock Information
- Founded
- LZ 2001
- ORKA 2004
- Country
- LZ United States
- ORKA United States
- Employees
- LZ N/A
- ORKA N/A
- Industry
- LZ EDP Services
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- LZ Technology
- ORKA Health Care
- Exchange
- LZ Nasdaq
- ORKA Nasdaq
- Market Cap
- LZ 1.5B
- ORKA 354.2M
- IPO Year
- LZ 2021
- ORKA N/A
- Fundamental
- Price
- LZ $9.12
- ORKA $12.60
- Analyst Decision
- LZ Hold
- ORKA Strong Buy
- Analyst Count
- LZ 9
- ORKA 8
- Target Price
- LZ $8.64
- ORKA $39.71
- AVG Volume (30 Days)
- LZ 1.7M
- ORKA 341.3K
- Earning Date
- LZ 08-06-2025
- ORKA 08-15-2025
- Dividend Yield
- LZ N/A
- ORKA N/A
- EPS Growth
- LZ 72.11
- ORKA N/A
- EPS
- LZ 0.17
- ORKA N/A
- Revenue
- LZ $690,777,000.00
- ORKA N/A
- Revenue This Year
- LZ $8.18
- ORKA N/A
- Revenue Next Year
- LZ $7.23
- ORKA N/A
- P/E Ratio
- LZ $53.27
- ORKA N/A
- Revenue Growth
- LZ 3.25
- ORKA N/A
- 52 Week Low
- LZ $5.33
- ORKA $5.49
- 52 Week High
- LZ $10.60
- ORKA $52.32
- Technical
- Relative Strength Index (RSI)
- LZ 58.00
- ORKA N/A
- Support Level
- LZ $8.48
- ORKA N/A
- Resistance Level
- LZ $9.14
- ORKA N/A
- Average True Range (ATR)
- LZ 0.20
- ORKA 0.00
- MACD
- LZ 0.02
- ORKA 0.00
- Stochastic Oscillator
- LZ 91.16
- ORKA 0.00
About LZ LegalZoom.com Inc.
LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States. The company also offers services that include ongoing compliance and tax advice and filings, business licenses, accounting, virtual mailbox and e-signature solutions, trademark filings, and estate plans.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.